Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy

Khon Kaen University18 enrolled

Overview

To evaluate the efficacy of intravitreal bevacizumab injections for treatment of proliferative diabetic retinopathy (PDR) with new dense vitreous hemorrhage (VH) after previous full panretinal photocoagulation (PRP).

The investigators will carry out a prospective study in patients with PDR and prior complete laser treatment who presented with new dense VH. All eyes will be treated with intravitreal injection of bevacizumab (1.25 mg). Complete ophthalmic examination and/or ocular ultrasonography will be performed at baseline and 1, 6, 12 weeks and 6, 9, 12 months after first injection. Re-injection will be done in non-clearing and recurrent VH.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Vitreous Hemorrhage Proliferative Diabetic Retinopathy

Interventions

intravitreal injection of bevacizumabDRUG

intravitreal injection of bevacizumab

Eligibility

Sex: ALLMin age: 20 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with diabetes mellitus * proliferative diabetic retinopathy * prior complete panretinal photocoagulation * presented with new dense vitreous hemorrhage Exclusion Criteria: * one-eyed patient * previous intraocular surgery * severe lens opacity precluding fundus examination * advance glaucoma * history of thromboembolic events such as myocardial infarction and cerebrovascular accident * uncontrolled systemic hypertension, systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg * known coagulation abnormalities or current use of anticoagulant medications other than aspirin * known allergies to any relevant drugs in this study * evidence of external ocular infection such as conjunctivitis and significant blepharitis.

Locations (1)

Srinagarind Hospital, Khon Kaen University

Khon Kaen, Changwat Khon Kaen, Thailand

Outcomes

Primary Outcomes

The percentage of eyes that vitreous hemorrhage has been completely resolved

The patients with PDR and prior complete laser treatment who presented with new dense VH. All eyes were treated with intravitreal bevacizumab injection. Complete ophthalmic examination and/or ocular ultrasonography were performed at baseline and 1, 6, 12 weeks and 6, 9, 12 months after first injection.

Time frame: 12 months

Secondary Outcomes

The change in best corrected visual acuity (BCVA) from baseline

The best corrected visual acuity (BCVA) was performed at baseline and 1, 6, 12 weeks and 6, 9, 12 months after first injection.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.